Comment on new CMS hospital price-transparency penalty

7 September 2020
cmsbig

The US Centers for Medicare & Medicaid Services (CMS) last week finalized a rule that would significantly toughen the penalty if hospitals fail to comply with the price-transparency mandate, which takes effect on January 1, 2021.

In doing so, the Trump administration has ratcheted up the pressure on hospitals to make public the prices they negotiate with private health insurers., says an expert observer.

“CMS will now require hospitals to report on a yearly basis the average rates they negotiate with Medicare Advantage plans,” explains Mark Polston, former CMS chief litigation counsel and a partner in King & Spalding’s Healthcare practice. “If a hospital fails to report that information, CMS has given itself the authority to deny all of the hospital’s Medicare reimbursement for the entire year -- a penalty that dwarfs the $300-per-day penalty CMS previously threatened," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical